Active weight loss phase begins in earnest
Routine liver function monitoring is not required for patients without pre-existing liver disease taking semaglutide
Physicians should observe for these adverse effects, notably in patients with comorbidities or polypharmacology
Anesthesiologists have been especially concerned about this risk after discovering patients on GLP-1 medications have gone into surgeries with lots of food left in their stomachs, which puts them at risk for this complication
A conceptual model of food cue reactivity, Nutrients (2023) Human drug compounding, Food and Drug Administration (2024) Compounding when drugs are on FDAs drug shortages list, Food and Drug Administration (2024) Your guide to FDA-approved medicines that contain semaglutide, Novo Nordisk FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food & Drug Administration (2024) Wegovy, DailyMed (2024) FDA warns patients and health care professionals not to use compounded drugs from Fullerton Wellness, Food and Drug Administration (2024) Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs, Novo Nordisk (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) OFA v
